Ketamine Troches vs. IV Infusion: A Complete Comparison

Ketamine troches vs IV infusion comes down to a tradeoff between precision and convenience. IV ketamine delivers the drug directly into the bloodstream in a monitored clinic setting, giving 100% bioavailability and the strongest research evidence for rapid antidepressant effect. Ketamine troches are compounded lozenges dissolved under the tongue at home, delivering roughly 20-30% of the labeled dose into circulation, at a fraction of the cost and without the logistics of clinic visits.

Ketamine is an NMDA receptor antagonist, a drug that blocks a specific glutamate receptor in the brain involved in mood regulation and pain signaling. It was originally developed as a surgical anesthetic and is now used off-label, and in the case of esketamine, on-label, for treatment-resistant depression. Neither route is universally better. The right choice depends on how severe and acute the depression is, what monitoring the patient needs, and what they can access and afford.

Bioavailability is the percentage of an administered drug dose that reaches the bloodstream intact and available to act on the body. It is the biggest pharmacological difference between these two delivery methods.

IV ketamine has 100% bioavailability. Every milligram prescribed enters the bloodstream directly, with nothing lost to digestion or absorption inefficiency. A standard treatment-resistant depression protocol dosed at 0.5 mg/kg over 40 minutes delivers 35 mg of ketamine with certainty for a 70 kg person.

Sublingual or buccal troches have an estimated bioavailability of 20-30%, according to StatPearls' clinical reference on ketamine pharmacology. A 200 mg troche therefore delivers roughly 40-60 mg of effective systemic ketamine, a dose in a similar range to a 35 mg IV infusion, but reached less predictably. Absorption varies between patients, and even between sessions in the same patient, depending on technique, salivary pH, how long the troche is held in place, and mucosal blood flow. Our guide to sublingual vs. buccal troche placement covers techniques that improve absorption consistency.

For research purposes and for patients who need tightly controlled plasma concentrations, IV remains the more reliable vehicle. For more on how quickly each format takes effect, see our troche onset, peak, and duration timeline.

IV ketamine has the strongest evidence base for rapid antidepressant effects in treatment-resistant depression. The landmark trial by Zarate and colleagues (2006) and many subsequent studies use IV administration, with response rates of 50-70% for depressive symptoms reported within 24 hours and many patients showing improvement after a single infusion. IV ketamine also has clear evidence for rapid antisuicidal effects, which is part of why it is used in crisis settings.

Evidence for sublingual and troche-based ketamine is growing but remains less extensive than for IV. Work by Andrade (2017) and outpatient clinical data show antidepressant effects comparable to lower-dose IV protocols in many patients, once the dose is calibrated for bioavailability. The correct comparison is not a 200 mg troche against a 0.5 mg/kg IV dose; it is the estimated systemic dose each route actually delivers.

Esketamine (brand name Spravato) is a related but distinct option: an intranasal formulation the FDA approved in 2019 for treatment-resistant depression, administered under supervision in a certified healthcare setting. It sits pharmacologically and logistically between IV infusion and at-home troches. Read our comparison of intranasal esketamine vs. ketamine troches for more detail.

For maintenance therapy specifically, oral and sublingual routes have practical advantages that lead many clinicians to use them after an initial acute course, often IV, with troches providing longer-term maintenance.

A single IV ketamine infusion in the United States typically costs $400-800 at a dedicated ketamine clinic. A standard acute protocol runs 6 infusions over 2-3 weeks, putting the total acute course at $2,400-4,800. Maintenance infusions, usually monthly, add another $400-800 per session.

Compounded ketamine troches typically cost $150-400 per month for a maintenance course of 2-4 sessions, depending on dose and pharmacy. Prescribing provider visits, an initial consultation plus monthly or bimonthly follow-ups, typically add $100-300 per month for telemedicine providers. Total monthly troche therapy cost runs roughly $250-700.

Over 12 months, troche therapy often costs meaningfully less than ongoing IV infusion, though the acute cost of a standard 6-infusion IV course can be comparable to several months of troche therapy. According to Healthcare.gov, out-of-pocket costs for treatments outside standard coverage fall entirely on the patient, and insurance rarely covers ketamine for psychiatric indications regardless of delivery route. For a full breakdown, see our guide on how much ketamine troches cost and our overview of the insurance coverage gap and patient assistance options.

IV infusions must happen in a clinical setting with trained staff and monitoring equipment. That means scheduling around clinic hours, arranging travel (often with a driver, since patients should not drive right after a session), and committing 1-2 hours per visit for setup, infusion, and recovery, across 6 or more sessions in the acute course.

Troches are taken at home, on the patient's own schedule, with no travel and less overall time commitment. That flexibility comes with a tradeoff: reduced professional monitoring during the session, which puts more responsibility on the patient to follow safety protocols. Our ketamine troche safety guide covers what that preparation should include.

During IV infusions, clinical staff monitor blood pressure and heart rate every 5-10 minutes, along with oxygen saturation, level of consciousness, and acute psychiatric response, and are trained to manage adverse events on-site. That real-time monitoring is IV ketamine's clearest safety advantage.

At-home troche sessions rely on the patient, and any support person present, to manage safety. There is no continuous vital sign monitoring, though a home blood pressure monitor is commonly recommended, and no immediate clinical intervention if a significant adverse effect occurs. Patients with significant cardiovascular risk, a history of adverse reactions to dissociatives, or significant psychiatric instability may be better served by clinic-based treatment where staff can respond directly.

Patients often describe IV ketamine as more intense and faster-reaching, since rapid delivery produces a sharper onset of dissociative effects. Some find the clinical environment reassuring; others find it cold or anxiety-provoking, and being removed from a familiar environment can be either stabilizing or limiting depending on the patient's goals.

The home setting and slower onset of troches are often described as gentler. Patients can fully control their environment, their own bed, music, and lighting, and for those who find clinical settings anxiety-inducing, that comfort can support better outcomes even with lower bioavailability.